top of page

WHAT IS AN "ART in Genomic Therapy" ? 

logo-inserm-rvb.png

The Technological Research Accelerator in Genomic Therapy (ART-TG) is an innovation center established by Inserm, the french national biomedical institution, to promote excellence in gene therapy research. 

 

ART-TG is a pre-GMP stage R&D laboratory aiming to bridge a gap between research and clinical or industrial applications. It has  pharmaceutical expertise for product development and product manufacturing, specifically for genomic therapy approaches. 

 

Therapeutic areas of interest are immunotherapy (cancer or infectious diseases), gene therapy of genetic diseases of the blood or immune system, two fields with high innovation potential and need for genomic therapy developments.

Inserm Transfert accompanies the partnerships of ART-TG.

The ART-TG accelerates the research and supports innovation of several Inserm units including:  

Integrare-UMR_S951, the Inserm unit of Genethon; Inserm U955-eq16 of the Vaccine Research Institute, Inserm UMR_S1163 at the Institute Imagine. 

IT UK.png
role of ART.png

TEAM  

Portrait A Galy_3 copie.jpg

Anne Galy, PhD, PharmD, DR Inserm

Director of ART-TG

 

Anne Galy is an expert in immunology and gene therapy with experience in early phase trials of gene therapy and in biotechnology.

ORCID iD

https://orcid.org/0000-0002-0153-4392

téléchargement.jpeg

Mario Amendola

PhD, CR1 Inserm

Advisor in genome editing

 

Mario Amendola is an expert in genome editing and gene therapy with international experience and a strong track record.

 

PARTNERS AND COLLABORATORS 

genopole.jpg
logo.png
LOGO_300dpi-copie.png
Logo_EFS.svg.png
logo-idf-2019_0.jpg
logo-dim-tg.jpg
logo-DIM1health-IDF-1.jpg
Fred_Hutch_logo.svg.png
Genethon.png
bottom of page